Rami Elghandour — SPARQNOW

At-a-Glance

Serves as Chairman and CEO of Arcellx, a biotechnology company acquired by Gilead for $8.2 billion in April 2026.
Previously President and CEO of Nevro Corporation, scaling it to a peak valuation of over $3 billion.
Led two successful IPOs and raised over $1.75 billion in capital across his career.
Served as a venture capitalist with Johnson and Johnson Development Corporation, investing in devices, biotechnology, and consumer products.
Recognized for advancing anito-cel, a therapeutic option for multiple myeloma.
Advocates for gender equity, diversity, and social justice, earning awards like EY Entrepreneur of the Year and the Bill Campbell Award.

Biography

Rami Elghandour is the Chairman and CEO of Arcellx, a biotechnology company focused on developing transformative immunotherapies for cancer and autoimmune diseases. Since joining in 2021, he transformed Arcellx from an early-stage startup into a leading organization, advancing anito-cel for multiple myeloma and driving a more than fortyfold increase in value with its $8.2 billion acquisition by Gilead in April 2026.